ACE-031
ACE-031 (Activin Receptor Type IIB Inhibitor)
A fusion protein that inhibits myostatin and related signaling pathways, dramatically increasing muscle mass. Developed for muscular dystrophy treatment.
Mechanism of Action
ACE-031 binds and neutralizes myostatin, GDF-11, activin A, and other TGF-beta family members that limit muscle growth. By blocking these inhibitory signals, it allows unrestricted muscle hypertrophy.
Health Claims & Evidence
Dramatically increases muscle mass
Reduces fat mass
Potential treatment for muscular dystrophy
Short-Term Effects
Rapid muscle mass increase, potential nosebleeds and telangiectasias (side effects from clinical trials).
Long-Term Effects
Sustained muscle hypertrophy. Long-term safety concerns from clinical trials led to program pause.
Side Effects
Nosebleeds, telangiectasias (small dilated blood vessels), gum bleeding — observed in clinical trials.
Contraindications
Use with extreme caution. Clinical trials were paused due to vascular side effects. Not recommended without medical supervision.
This profile is provided for educational research only. It is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Verify primary sources and consult a qualified healthcare professional for medical decisions.
Research Papers
ACE-031 and muscle mass in healthy volunteers
Attie et al. · Muscle & Nerve · 2013
Educational research only. This profile is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Consult a qualified healthcare professional for medical decisions.
Related Peptides
Explore the research further
Our AI Research Advisor can help you explore the evidence on ACE-031 and related peptides, and prepare an educational research summary.
Explore Research